Long School of Medicine

KSAT 12: San Antonio doctor stresses importance of routine mammograms during pandemic

October 22, 2020

Dr. Kate Lathrop, Medical Oncology/Mays Cancer Center, speaks to audiences of KSAT 12 TV during this Breast Cancer Awareness month, stressing the safety of doctors’ office visits and the importance of routine mammograms during the pandemic. Read and watch the story.

WebMD: Many baby boomers not tested for hep C despite risk

October 22, 2020

Dr. Waridibo Allison, Infectious Diseases, is quoted in this story about a WebMD survey that shows despite the CDC recommendation that every baby boomer be screened for hepatitis C that many aren’t. Read the story. 

The Texan: Texas Receives $104 Million Federal Grant to Fight Opioid Epidemic

October 22, 2020

Jennifer Potter, PhD, MPH, and the $12 million grantt she received to fight the opioid epidemic, are mentioned in this story. Dr. Potter is a professor of psychiatry, vice dean for research in the School of Medicine and associate vice president for South Texas Public Health Initiatives. Read the story.

KSAT 12: When will we see a COVID-19 vaccine? UT Health infectious disease expert weighs in

October 20, 2020

Dr. Jason Bowling, Infectious Diseases, weighs in on when we might see a COVID-19 vaccine by breaking down the steps in vaccine development. Read and watch the interview.

Drug Target Review: SARS-CoV-2 papain-like protease could be a novel drug target

October 20, 2020

Researchers from UT Health San Antonio, US, and the Wroclaw University of Science and Technology, Poland, found that SARS-CoV-2-PLpro promotes infection by sensing and processing both viral and human proteins. Read the story.

KSAT 12: WHO study finds remdesivir didn’t help COVID-19 patients; UT Health weighs in

October 19, 2020

KSAT 12 localized the national story involving a statement of the World Health Organization (WHO) with an interview of Dr. Thomas Patterson, Infectious Diseases, who is leading a UT Health San Antonio-University Health System study site on remdesivir, as part of the Adaptive COVID-19 Treatment Trials (ACTT) sponsored by the National Institute of Allergy and […]